Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotech-beach symbols : Amgn save search
Xencor Reports Third Quarter 2023 Financial Results
Published: 2023-11-07 (Crawled : 00:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.05%
H: 1.41%
C: 0.82%
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: -1.47%
H: 11.57%
C: 5.97%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 0.36%
H: 0.48%
C: -1.09%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.09%
H: 0.35%
C: -0.57%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.05%
H: 0.38%
C: -0.68%
financial results
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.5%
H: 2.69%
C: -0.09%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.94%
H: 1.82%
C: 1.25%
krystexxa blood show
AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE - September 7, 2023
Published: 2023-09-07 (Crawled : 21:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.12%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.61%
H: 1.66%
C: 1.54%
conference global
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.74%
H: 1.16%
C: 0.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.9%
H: 0.0%
C: -0.58%
humira biosimilar
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: -0.21%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.44%
C: 0.24%
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: 1.32%
H: 1.12%
C: 0.34%
FLGT | $20.34 1.14% 1.13% 160K
|
Health Services
|
| O: 0.43%
H: 3.12%
C: 0.85%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.7%
H: 4.68%
C: 3.43%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.06%
H: 0.81%
C: -0.01%
NEUVOGEN Appoints Stephen A. Sherwin, M.D. to its Scientific Advisory Board
Published: 2022-07-25 (Crawled : 16:00) - biospace.com/
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: 0.0%
H: 2.1%
C: -0.89%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 0.25%
H: 0.51%
C: -0.29%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.99%
H: 0.99%
C: 0.38%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.13%
H: 0.95%
C: 0.77%
ANIP S | $65.49 1.41% 1.39% 210K
|
Health Technology
|
| O: 0.79%
H: 7.5%
C: 5.09%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.37%
H: 0.9%
C: 0.75%
Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer
Published: 2022-03-01 (Crawled : 14:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: -0.62%
H: 4.5%
C: -5.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
therapeutics
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
Published: 2022-01-11 (Crawled : 15:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
therapeutics collaboration
Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference
Published: 2021-09-13 (Crawled : 00:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.55%
H: 0.92%
C: -0.16%
conference
Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
Published: 2021-06-23 (Crawled : 09:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.74%
H: 2.99%
C: 2.16%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
migraine approval
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Published: 2021-06-01 (Crawled : 09:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.79%
H: 0.03%
C: -3.56%
treatment potential dermatitis phase 3 atopic dermatitis
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Published: 2021-02-16 (Crawled : 00:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.51%
H: 0.71%
C: -1.34%
treatment fda lung cancer cancer designation
Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference
Published: 2021-01-06 (Crawled : 00:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.21%
H: 3.79%
C: 3.67%
j.p. morgan healthcare conference
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.